文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

淋球菌抗菌药物耐药快速检测的现状与新兴技术

Current and Emerging Approaches and Technologies for Rapid Detection of Neisseria gonorrhoeae Antimicrobial Resistance.
PubMed 文献 · Clin Infect Dis · 2026-01-01

综述指出淋球菌耐药率上升威胁淋病治疗,抗菌药物敏感性检测(AST)并非常规开展。文章梳理已上市和在研的淋球菌耐药快速检测方法,并讨论可在床旁(POC)实施的核酸类表型新方法及落地问题。

要点

  • 淋球菌耐药上升,AST 非常规开展,POC 耐药检测可指导治疗。
  • 已上市与在研的淋球菌耐药快速检测方法构成本文综述对象。
  • 核酸类表型新方法有望用于 POC 耐药指导治疗。

核心结论

  • 淋球菌耐药率上升对淋病未来治疗构成挑战,POC 耐药检测可辅助指导治疗并支持既往推荐方案再使用。

研究设计与样本

  • 综述,检索范围包括已上市和研发中的淋球菌耐药快速检测方法及核酸类表型新方法。

主要发现

  • 已梳理淋球菌耐药快速检测的商业化产品与在研技术,并讨论核酸类表型方法在 POC 耐药指导治疗中的潜在应用。

临床怎么用

  • 在 POC 检测淋球菌耐药可指导治疗选择,包括重新使用既往推荐的淋病治疗方案。

局限性

  • POC 耐药检测的实施仍存在待讨论的问题。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The increasing rates of antimicrobial resistance (AMR) in Neisseria gonorrhoeae (NG) pose a challenge to the successful future treatment of gonorrhea. Although antimicrobial susceptibility testing (AST) is not routinely performed for NG, detection of antimicrobial susceptibility at the point-of-care (POC) could help guide treatment, including the re-use of previously-recommended treatment. We review the landscape of commercially-available tests and those under development for the rapid determination of AMR in NG. Additionally, we discuss the performance of new and novel nucleic acid-based phenotypic approaches for rapid characterization of AMR, which could potentially be implemented at the POC for resistance-guided therapy. Lastly, issues regarding the implementation of POC tests for resistance testing are discussed.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Melendez JH, Manabe YC. Current and Emerging Approaches and Technologies for Rapid Detection of Neisseria gonorrhoeae Antimicrobial Resistance. Clin Infect Dis. 2026. PMID: 41504562. doi:10.1093/cid/ciaf517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。